Novo Nordisk sued rival Eli Lilly in a U.S. federal court on July 21, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo’s drugs. The Danish company filed the lawsuit in U.S. District Court in New Jersey, alleging Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for obesity drug Zepbound and diabetes treatment Mounjaro. Novo alleges Lilly compared the highest approved […]

Read more

With the increase in the use of GLP-1 drugs like Ozempic, a Saskatoon group focused on body positivity says a message from a local doctor left them questioning how the medications are being promoted and prescribed. It came in the form of a Facebook message that Cierra Giesbrecht, the founder of The Curvy Club, thought was a troll at first. “At first, I thought it was a troll,” Giesbrecht told Global News. “I couldn’t believe that an […]

Read more

I didn’t start strength training because I wanted sculpted arms or visible abs, though I certainly wouldn’t complain about either. I started because I suddenly needed to be stronger. Last year, when my roommate and best friend Monica’s dog, Indigo, became partially paralyzed after an injury, daily life changed overnight. I was lifting a 70-pound pit bull into the car for vet appointments, onto beds, and outside to use the bathroom multiple times a day. It did […]

Read more

GLP-1 medications are considered long-term treatments. Studies show that most people regain weight after stopping these medications, as their appetite returns. “GLP-1s are like stepping on the brakes, inducing satiety and making you feel fuller,” Simonetti says. “If you take your foot off the brake, those other mechanisms come back up.” This is similar to those who take medication for high blood pressure or for diabetes.  “If their blood pressure improves, or the diabetes improves, it doesn’t […]

Read more

With about 74% of U.S. adults meeting criteria for being overweight or obese — and studies on obesity suggesting nearly half of U.S. adults could be considered obese by 2030 — the need for safe, effective and accessible weight management care continues to grow. Maintaining a healthy weight is essential to preventing many health complications and chronic conditions, including hypertension, type 2 diabetes, coronary heart disease and certain cancers. But making weight-conscious lifestyle choices is not always […]

Read more

The Food and Drug Administration on Wednesday approved a new weight loss pill from drugmaker Eli Lilly. The daily pill, called Foundayo, is the second oral GLP-1 to reach the market in recent months, following the approval of Novo Nordisk’s Wegovy pill in December. Foundayo will be offered in six doses, with patients typically starting on the lowest dose and working their way up to reduce side effects. It can be taken at any time of day […]

Read more

Hormones play a role too. When an individual tries to lose weight, it triggers a powerful hormonal response that tells your body to regain the weight you lost. Cummings explains that because of this, the brain interprets a calorie drop as an energy deficiency, so after stopping weight-loss drugs, hormones that stimulate appetite increase while the rate at which you burn energy – the metabolic rate – decreases. “If these biological defences are strong enough, they can […]

Read more

Overview of study recruitment Participants in this study were recruited from the customer base of 23andMe. Participants provided informed consent and volunteered to participate in the research online, under a protocol approved by the external Association for the Accreditation of Human Research Protection Programs-accredited Salus Institutional Review Board (https://www.versiticlinicaltrials.org/salusirb). Participants were included in the analysis on the basis of consent status verified at the time data analyses were initiated. The 23andMe GLP1 survey was launched to research […]

Read more

  Key Insights The current range of weight-loss drugs on the market targets GLP-1 receptors. Seeking a new generation of weight-loss drugs, some companies are developing amylin analogs. As clinical trial data around amylin analogs emerge, investors worry about the amount of weight loss the molecules can offer. For the past 7 years, pharmaceuticals that work as glucagon-like peptide 1 (GLP-1) receptor agonists have dominated the weight-loss and diabetes markets. These drugs, currently sold by Novo Nordisk […]

Read more

New research from 23and ME sheds a light on why GLP-1 weight-loss drugs work differently across patients, with two studies suggesting that genetic variation and cardiovascular mechanisms independent of weight loss may both play significant roles in determining individual outcomes. Emerging Pharma Leaders nominations are now open! Do you know someone who can make tough decisions that continue to face manufacturers? Are they destined to change the future of pharma? Nominate a colleague with impressive leadership and […]

Read more